Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336317 | 0.87 | KDM4E (0.47) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL26415066 | 0.83 | CYP4F2 (0.34) | CYP4F2CYP4A11KDM4E | |
| SCHEMBL29347208 | 0.76 | CYP4F2 (0.36) | CYP4F2CYP4A11 | |
| SCHEMBL10036713 | 0.72 | MEN1 (0.40) | CYP4F2CYP4A11KDM4EMEN1MAPT | |
| SCHEMBL6629252 | 0.72 | CYP4F2 (0.61) | CYP4F2CYP4A11KDM4EMEN1MAPT | |
| SCHEMBL19838495 | 0.71 | TACR1 (0.44) | MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL13687308 | 0.71 | KDM4E (0.33) | KDM4EMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL14857995 | 0.71 | CYP4F2 (0.59) | CYP4F2CYP4A11KDM4EMEN1MAPT | |
| SCHEMBL14858868 | 0.71 | CYP4F2 (0.59) | CYP4F2CYP4A11KDM4EMEN1MAPT | |
| SCHEMBL14857809 | 0.71 | CYP4F2 (0.59) | CYP4F2CYP4A11KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097634-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110257212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257212-A1 | NEW AZACYCLIC DERIVATIVES | LIPE, GPR119, LPL | CYP4F2 886/4885CYP4A11 110/4885KDM4E 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.